These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 20944178)
1. Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial. Yamamoto D; Iwase S; Yoshida H; Kuroda Y; Yamamoto C; Kitamura K; Odagiri H; Nagumo Y Anticancer Res; 2010 Sep; 30(9):3827-31. PubMed ID: 20944178 [TBL] [Abstract][Full Text] [Related]
2. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine. Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Shien T; Shimizu C; Akashi-Tanaka S; Yonemori K; Kohno T; Hojo T; Ando M; Katsumata N; Kinoshita T; Fujiwara Y Jpn J Clin Oncol; 2008 Mar; 38(3):172-5. PubMed ID: 18296424 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
8. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117 [TBL] [Abstract][Full Text] [Related]
10. [A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1]. Inoue H; Yano H; Shimabukuro R; Shiraishi T; Takahashi I; Nishizaki T; Murakami M Gan To Kagaku Ryoho; 2010 Dec; 37(13):2909-11. PubMed ID: 21160268 [TBL] [Abstract][Full Text] [Related]
11. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129 [TBL] [Abstract][Full Text] [Related]
13. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617 [TBL] [Abstract][Full Text] [Related]
14. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418 [TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193 [TBL] [Abstract][Full Text] [Related]
16. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775 [TBL] [Abstract][Full Text] [Related]
17. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245 [TBL] [Abstract][Full Text] [Related]
18. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK. Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]